U.S. Markets open in 1 hr 30 mins

Meridian Bioscience, Inc. (VIVO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.59+0.18 (+1.17%)
At close: 4:00PM EDT

Meridian Bioscience, Inc.

3471 River Hills Drive
Cincinnati, OH 45244
United States
513-271-3700
http://www.meridianbioscience.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees660

Key Executives

NameTitlePayExercisedYear Born
Mr. John P. KennyPres, CEO, Exec. VP of Diagnostics Bus. Unit & Director831.14kN/A1969
Mr. Bryan BaldasareExec. VP, Chief Accounting Officer, CFO & Sec.333.2kN/AN/A
Dr. Lourdes G. WeltzienExec. VP of Life Science Bus. Unit432.93kN/AN/A
Ms. Melissa A. LuekeConsultant190.34kN/A1963
Mr. Jeff PinkstonDirector of Corp. Fin.N/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; rapid fluorescence-based immunoassay platform under the Curian brand; rapid single-use immunoassays under the ImmunoCard and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare and PediaStat brands. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of gastrointestinal assays, including tests for C. difficile, Enterohemorrhagic E. coli, Campylobacter jejuni, H. pylori, Cryptosporidium, giardia lamblia, and calprotectin; respiratory illness assays, such as tests for Group A Streptococcus, Influenza, M. pneumoniae, Bordetella pertussis, and respiratory syncytial virus; blood chemistry assays; and tests for Group B Streptococcus, Chlamydia trachomatis, Neisseria gonorrhea, Herpes Simplex Virus Type 1 and Type 2, and Malaria. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by researchers, agri-bio companies, and IVD manufacturing companies. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.

Corporate Governance

Meridian Bioscience, Inc.’s ISS Governance QualityScore as of December 9, 2019 is 6. The pillar scores are Audit: 5; Board: 1; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.